You are here

Award Data

For best search results, use the search terms first and then apply the filters

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel commensal polysaccharide treats multiple sclerosis through Treg modulation


    DESCRIPTION provided by applicant Multiple sclerosis MS is a chronic demyelinating inflammatory disease that is the most common neurological disease of young adults affecting over patients in the US and over million patients worldwide MS is a disease of high unmet medical need currently treatable with one of twelve FDA approved drugs all of which result in either significant i ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health

    SBC: CALIBRANT BIOSYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Because of the long history of the use of formalin as the standard fixative for tissue processing in histopathology, there are a large number of archival formalin-fixed and paraffin-embedded (FFPE) tissue banks worldwid e. These FFPE tissue collections, with attached clinical and outcome information, present invaluable resources for conducting retrospective pro ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  3. Development and testing of a behavioral activation mobile therapy for elevated depressivesymptoms

    SBC: MOUNTAINPASS TECHNOLOGY LLC            Topic: 104

    PROJECT SUMMARY/ABSTRACT Depression is the leading cause of disability worldwide, with more than 300 million people affected. Most adults with depressive symptoms make at least one annual visit to a primary care physician (PCP). As such, primary care offers a ripe opportunity to identify and treat adults with depressive symptomatology. Yet, depression has historically been undertreated in primary ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  4. CG-GRID: Computational Genetics Grid Resource for Interaction Discovery

    SBC: PARABON COMPUTATION, INC.            Topic: 400

    DESCRIPTION provided by applicant Advances in DNA sequencing technology have now made it practical and affordable to generate datasets containing millions of genetic attributes that can be tested for association with disease susceptibility The computational complexity of searching for genetic interactions over such high dimensional datasets imposes great challenges for genome wide associatio ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. An Efficacy Trial of a Digital Therapeutic for Suicide Prevention

    SBC: Oui Therapeutics, LLC            Topic: NIMH

    ABSTRACT Suicide is one of the top ten causes of death in the US and suicide rates have increased steadily over the last twenty years. Currently, the most effective treatment options are cognitive behavioral therapies for suicide prevention (CBT-SP), which have been shown to reduce both suicide attempt (SA) risk and suicide ideation (SI). However, access to these treatments is limited because ther ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  6. High Resolution Digital Imaging X-ray Detectors

    SBC: Aguila Technologies, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The aim is to develop a high resolution, high contrast detector for digital x-ray imaging systems. The target detector would have a Detective Quantum Efficiency much greater than 80%, a limiting resolution of at least 10 lp/mm, ultra-low noise, linear response and a dynamic range of more than 14 bits. The proposal is to build such a detector by using CdZnTe c ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a low-cost hardware accelerator for 3D image registration

    SBC: IGI TECHNOLOGIES, INC            Topic: 102

    DESCRIPTION provided by applicant Our overall goal is to develop a novel computing solution for automatic and accurate registration spatial alignment of dimensional D medical images of any modality and any anatomy rigid or deformable in minute or less Such capability currently does not exist Existing image registration solutions have limited accuracy and or limited applicability p ...

    STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health

    SBC: VERACHEM LLC            Topic: N/A

    Today, promising new protein targets for small molecule drugs are being discovered rapid. With increasing frequency, the 3D structures of these proteins are available or can be modeled from known protein structures. Demand is therefor growing for software to support structure-based discovery of protein ligands as candidate drugs. However, existing software leaves enormous room for improvement in a ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  9. Tritum AMS Analysis of Cancer Biomarkers

    SBC: NEWTON SCIENTIFIC, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this Phase II STTR program is to develop a high-throughput, ultra-sensitive accelerator mass spectrometer for the detection and quantification of tritium in labeled biological molecules. Accelerator mass spectrometry (AMS) is a highly selective means for detecting tritium that can achieve a measurement sensitivity over 1000 times greater than decay ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  10. New Rapid Diagnostic Tests for Amebiasis

    SBC: TECHLAB, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Our goal is to produce point-of-care diagnostic tests for amebiasis. Entamoeba histolytica is a protozoan parasite and the causative agent of amebiasis in humans. Intestinal amebiasis causes debilitating diarrhea and dysentery, while extraintestinal amebiasis occurs when the parasite migrates from the intestinal tract to organs throughout the body, most commonl ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government